A year has passed since I wrote about the trials and tribulations of Obagi Medical Products (Nasdaq:OMPI) and the effect they were having on its stock price. I suggested its losses in Texas presented an opportunity for investors willing to take a risk. Since then its stock is up 39%, its Texas problems behind it, and a future that's brighter than ever. With larger cosmetic companies rumored to be interested in its proprietary skin care systems, another 39% move over the next 12 months is a reasonable expectation.

Investopedia Broker Guides: Enhance your trading with the tools from today's top online brokers.
Texas Troubles
Obagi's problems go all the way back to November 2009 when the Texas Department of State Health Services sent the company a letter suggesting it was shipping products containing unapproved new drugs in the state of Texas. Eventually, Obagi voluntarily ceased shipping any products containing 4% hydroquinone (HQ) from April 2011 through Feb. 29, 2012, at which time the Attorney General of Texas closed its investigation, rendering no penalties against the company. Obagi reintroduced its HQ products into the Texas market in May. The entire ordeal cost the company $3.9 million in sales returns and inventory in 2011.

At the same time the Texas government was dropping the matter, the state of California was just getting started. In February 2012, the California Attorney General's (CAG) office subpoenaed Obagi seeking to determine whether its business practices regarding its HQ products were reasonable. Clearly, this is politically motivated because Texas just finished investigating the matter for 27 months and found no evidence of any wrongdoing. Why the CAG feels the need to get involved at this point is a bit of a mystery, and while Obagi should prevail in California's inquiry, it is a time consuming and unnecessary distraction.

First Quarter Results
They were solid. Revenues increased 16% in Q1 to $30.8 million, its best quarter ever. In terms of operating profits, if you add back the $7.2 million in pre-tax litigation and settlement costs with founder Zein Obagi, they increased roughly 48% year-over-year to $4.9 million. Gross margins improved 30 basis points to 79.7% and operating margins 340 basis points to around 16%. Nu-Derm, its largest product in terms of sales, which accounts for slightly more than 50% of revenue, increased 18% year-over-year to nearly $15.6 million. Included in its operating expenses was a $1.5 million investment for the creation of an e-commerce platform and online pharmacy.

In total, it plans to spend between $9 million and $12 million getting it up and running in 2012, and expects it will recoup its investment within 12 months and another $2- 3 million to keep it running every year. The initiative will reduce its 2012 earnings by at least 29 cents per share. Revenues in 2012 should be around $119 to $124 million, with earnings per share of between 58 cents and 62 cents, which includes the e-commerce expenses mentioned previously. The future looks promising, especially if the e-commerce platform gains traction.

SEE: Earnings Forecasts: A Primer

Takeover Target
In early March, rumors surfaced that Obagi was a takeover candidate because it introduced a rights plan to treat all shareholders equally should a third party attempt to obtain part or all of the company. The rumors died down, but now seems to have resurfaced. Analysts at Cantor Fitzgerald, Canaccord Genuity and Roth Capital all have "buy" ratings on its stock and word is the company is entertaining several offers including a $20-plus offer from a major cosmetics company.

Cantor Fitzgerald analyst Irina Rivkind believes a possible candidate is Medicis Pharmaceutical (NYSE:MRX), which recently announced that $450 million in new financing that will be used for M&A activity. Other potential candidates include L'Oreal (OTCBB:LRLCY), Valeant Pharmaceuticals (NYSE:VRX) and Allergan (NYSE:AGN). Recently, Fougera was sold for 3.55 times sales, suggesting an offer could be as high as $23 a share should one appear.

SEE: Mergers & Acquisitions: An Avenue For Profitable Trades

The Bottom Line
Obagi is the perfect tuck-in acquisition for any of the names mentioned above. I'd be shocked if an offer didn't appear by the end of the summer. At $23, you're looking at a 77% return in just three months. The downside risk appears minimal at the moment, while the upside is huge. Swing away.

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

At the time of writing, Will Ashworth did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Investing

    The ABCs of Bond ETF Distributions

    How do bond exchange traded fund (ETF) distributions work? It’s a question I get a lot. First, let’s explain what we mean by distributions.
  2. Stock Analysis

    The 5 Best Dividend Stocks in the Healthcare Sector

    Learn about the top five dividend stocks of companies operating in the health care sector that generate substantial cash flows to afford high payouts.
  3. Stock Analysis

    3 Stocks that Are Top Bets for Retirement

    These three stocks are resilient, fundamentally sound and also pay generous dividends.
  4. Investing News

    Are Stocks Cheap Now? Nope. And Here's Why

    Are stocks cheap right now? Be wary of those who are telling you what you want to hear. Here's why.
  5. Investing News

    4 Value Stocks Worth Your Immediate Attention

    Here are four stocks that offer good value and will likely outperform the majority of stocks throughout the broader market over the next several years.
  6. Investing News

    These 3 High-Quality Stocks Are Dividend Royalty

    Here are three resilient, dividend-paying companies that may mitigate some worry in an uncertain investing environment.
  7. Stock Analysis

    An Auto Stock Alternative to Ford and GM

    If you're not sure where Ford and General Motors are going, you might want to look at this auto investment option instead.
  8. Mutual Funds & ETFs

    The 4 Best Buy-and-Hold ETFs

    Explore detailed analyses of the top buy-and-hold exchange traded funds, and learn about their characteristics, statistics and suitability.
  9. Mutual Funds & ETFs

    What Exactly Are Arbitrage Mutual Funds?

    Learn about arbitrage funds and how this type of investment generates profits by taking advantage of price differentials between the cash and futures markets.
  10. Investing News

    Ferrari’s IPO: Ready to Roll or Poor Timing?

    Will Ferrari's shares move fast off the line only to sputter later?
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  5. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center
You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!